Literature DB >> 6958215

Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

R Auckenthaler, W R Wilson, A J Wright, J A Washington, D T Durack, J E Geraci.   

Abstract

The minimal bactericidal concentrations of N-formimidoyl thienamycin (N-f-thienamycin) against 21 strains of enterococci isolated from patients with infective endocarditis were determined by macro- and microdilution methods. By a macrodilution technique with the minimal bactericidal concentration defined as greater than or equal to 99.9% killing of an initial inoculum, all 21 strains of enterococci were found to have minimal bactericidal concentration/minimal inhibitory concentration ratios of greater than or equal to 32. The mean minimal inhibitory concentration was 1.5 micrograms/ml (range, 0.5 to 4 micrograms/ml), and the minimal bactericidal concentration was greater than or equal to 128 micrograms/ml. The disparity between the results of our study and those published elsewhere, which reported that N-f-thienamycin is bactericidal in vitro against enterococci, may represent the relative insensitivity of the microdilution method in determining greater than or equal to 99.9% killing. The lack of in vitro bactericidal activity of N-f-thienamycin against enterococci was confirmed in vivo in the rabbit model of experimental endocarditis. N-f-Thienamycin was no more effective than penicillin alone in the treatment of experimental enterococcal endocarditis and was less effective than the combination of penicillin and gentamicin. The results indicate that N-f-thienamycin should not be used alone in the treatment of enterococcal endocarditis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958215      PMCID: PMC183764          DOI: 10.1128/AAC.22.3.448

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In-vitro methods for determining minimal lethal concentrations of antimicrobial agents.

Authors:  A L Barry; R A Lasner
Journal:  Am J Clin Pathol       Date:  1979-01       Impact factor: 2.493

2.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

3.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

4.  Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

Authors:  J S Kahan; F M Kahan; R Goegelman; S A Currie; M Jackson; E O Stapley; T W Miller; A K Miller; D Hendlin; S Mochales; S Hernandez; H B Woodruff; J Birnbaum
Journal:  J Antibiot (Tokyo)       Date:  1979-01       Impact factor: 2.649

5.  Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

6.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

9.  N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.

Authors:  D Hanslo; A King; K Shannon; C Warren; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

10.  Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.

Authors:  P K Garrison; L R Freedman
Journal:  Yale J Biol Med       Date:  1970-06
  10 in total
  16 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.

Authors:  E Debbia; A Pesce; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 4.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

5.  Synergistic effect of N-formimidoyl thienamycin with gentamicin and amikacin against Streptococcus faecalis.

Authors:  M E Gombert; L B Berkowitz; M C Cummings
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

6.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 7.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 8.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

9.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group.

Authors:  S Gordon; J M Swenson; B C Hill; N E Pigott; R R Facklam; R C Cooksey; C Thornsberry; W R Jarvis; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

Review 10.  Technical aspects and clinical correlations of the serum bactericidal test.

Authors:  H C Standiford; B A Tatem
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.